Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
4.430
+0.230 (5.48%)
At close: May 12, 2025, 4:00 PM
4.430
0.00 (0.00%)
After-hours: May 12, 2025, 4:00 PM EDT
Foghorn Therapeutics Revenue
In the year 2024, Foghorn Therapeutics had annual revenue of $22.60M, down -33.83%. Foghorn Therapeutics had revenue of $2.86M in the quarter ending December 31, 2024, a decrease of -50.49%.
Revenue (ttm)
$22.60M
Revenue Growth
-33.83%
P/S Ratio
10.76
Revenue / Employee
$201,804
Employees
112
Market Cap
246.36M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
FHTX News
- 7 days ago - Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference - GlobeNewsWire
- 11 days ago - Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewsWire
- 14 days ago - Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update - GlobeNewsWire
- 27 days ago - Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting - GlobeNewsWire
- 6 weeks ago - Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting - GlobeNewsWire
- 2 months ago - Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook - GlobeNewsWire
- 2 months ago - Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities - GlobeNewsWire